After the Rotterdam Marathon on 21 April 1991 (ambient temperature 5.80C, relative humidity 74%, wind velocity 5 m s-1) data from 66 athletes were analysed for information concerning total recovery and recovery from pain, stiffness, loss of appetite, sleep disturbance and fatigue.
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The pulse rate, body weight and temperature were measured. The athletes were divided at random into two groups. Thirty-four athletes received an intravenous infusion of 2.51 of a 2.5% glucose/0.45% NaCl solution. Thirty-two athletes received a placebo infusion of 100ml 0.9% NaCl. Recovery took 9.2 days in the placebo group and 10.2 days in the infusion group. All athletes had pain and/or stiffness after the marathon. The immediate replacement of 2.51 of fluid had no significant influence on the rate of total recovery, the number of days with pain or stiffness, the appetite, sleep or fatigue. On the first day after the marathon the pulse rate was increased. The rectal temperature was not affected. The athletes were also divided into fast and slow runners without regard to fluid replacement. Fast runners (those running the race in less than 2 h 55 min) needed more time to recover than slower runners and pain and/or stiffness lasted longer in the fast group. Athletes who equalled or improved their best previous result also needed more A search of the literature showed that there are almost no data available dealing with recovery after a marathon race. Therefore a study was designed to gather information about the recovery of marathon runners and the effect of intravenous fluid infusion immediately following the race.
Subjects and methods
Our study population was chosen from the list of competitors. Experienced male marathon runners were selected. Only those who had completed a previous marathon in less than 3 h and were members of a Dutch track and field club were entered in the study. Of the 382 athletes who fulfilled the above requirements 263 were selected because they lived in, or in the vicinity of, Rotterdam, or in one of the other big cities in the Netherlands. These 263 athletes were asked by informative letter to participate in our investigation. We received a positive response from 98 athletes. The athletes were divided at random into two groups. The participants in each group were to receive an i.v. infusion (100ml 0.9% NaCl in group 1 and 2.512.5% glucose/0.45% NaCl in group 2) administered by anaesthetists and their auxiliaries. The infusions were administered to groups 1 and 2 in separate rooms. All athletes had a cooling down period of approximately 30 min. The 100-ml infusion took on average 15 min, whereas the 2.5-1 infusion was completed after about 50min. Questions concerning recovery, pain, stiffness, loss of appetite, sleep disturbance and fatigue, were answered by the athletes on the 36 days following the marathon by filling in a questionnaire. The questions were answered by using a visual analogue scale of 0-10. On days 1, 3, 7, 14 and 21 the athletes were asked to determine their weight, pulse rate and rectal temperature. All athletes received the fullest possible written information about the aims and methods of the investigation. They gave written consent and the protocol of the study was approved by the Medical Ethics Committee of the Medical Faculty and the University Hospital of Rotterdam. On the day of the marathon 17 athletes failed to appear and 11 athletes dropped out of the race before the finish. One athlete was in poor physical condition and on medical grounds he was given the 2.5-1 infusion instead of the Table 2 . A graph of the cumulative percentage of recovered athletes is given in Figure 1 .
Pain and stiffness
The athletes were asked to classify their muscle pain and/or stiffness on a 0-10 visual analogue scale (0 = maximal pain/stiffness, 10 = no pain/stiffness) during the 36 days following the marathon. There were no significant differences between group 1 and group 2 although group 2 showed a tendency to have longer and more muscle pain and stiffness. The nonsignificant increased stiffness in group 2 (2. Figure 2 shows the decreasing percentage of athletes having muscle pain in the days following the marathon. Figure 3 shows the average level of muscle pain after the marathon. Figure 4 shows the percentage of athletes experiencing stiffness and Figure 5 Pulse rate, body weight and temperature All athletes were asked to measure their pulse rate, body weight and temperature on days 1, 3, 7, 14 and 21 after the marathon. Running the marathon did not affect the rectal temperature. There was no difference between groups 1 and 2. The weight of the athletes in the placebo group (group 1, 100 ml 0.9% NaCl) rose to normal from day 1 to day 3. The difference between the two groups was significant (P < 0.001). There was no weight change in athletes who received the 2.5-1 infusion. The pulse rate showed a significant elevation on day 1 in comparison with day 3 (P < 0.001). This was the case for both groups. There was no significant difference between the groups. The average pulse rate of the athletes was about 50-52 beats min'. A pulse rate below 50 beats min-was quite common.
Influence of velocity and amount of strain Comparing the results of groups 1 and 2 we see that group 2, who received the 2.5-1 infusion, was not doing better than group 1. On the contrary, group 2 required more time to recover, they had more muscle pain that lasted longer, and they had more stiffness for longer. Although these differences were not significant they were consistent. As can be judged from Table 1 there were no appreciable differences between the two groups before they entered the marathon. However, there was a difference at the finish. Group 2 was faster than group 1. Group 1 reached the finish in an average time of 3 h 1 min (181 min), group 2 had an average time of 2 h 52 min (172min). This difference was statistically significant (P = 0.015). Our findings might suggest that fast athletes need more time to recover and also have more and longer muscle pain and/or stiffness. If we compare the mean best marathon time (the average of the personal best marathon times of the groups) with the time used in this marathon, we find that group 1 performed below their average. Group 2 approached their capabilities more closely. Eight of group 1 improved or ran as fast as their personal best marathon time whereas 19 of group 2 improved or ran as fast as their best time. This suggests that an athlete who makes a greater demand on his resources needs more time to recover and has more and longer muscle problems. To investigate the possible influence of the velocity of the runner we divided the 66 runners into 'slow' and 'fast' groups, regardless of the amount of fluid they received after the marathon. All athletes who ran faster than 2h 55 min (175 min) formed group A, all athletes who ran slower than this formed group B. We found that the 'fast' athletes recovered significantly more slowly P = 0.026) and had more (P = 0.030) muscle pain than the 'slow' athletes. Group A needed on average 12.5 days to recover, group B needed on average 6.9 days to recover. There was no significant difference in duration of muscle pain, stiffness, fatigue and appetite. To investigate the possible influence of the amount of strain of the runner we divided the 66 runners into a group of athletes who improved or ran as fast as their best time (group X) and a group of athletes who performed below their capabilities (group Y). We found that group X recovered significantly more slowly than group Y (p = 0.013). Group X needed on average 12.8 days to recover whereas group Y needed on average 7.4 days. There was no significant difference in muscle pain, stiffness, fatigue, sleep and appetite. We conclude that the velocity of the runner and the amount of strain undergone by the athlete have certain effects on recovery after running a marathon.
